Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City, 46956 [2016-17061]

Download as PDF 46956 Federal Register / Vol. 81, No. 138 / Tuesday, July 19, 2016 / Notices INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–964] Certain Windscreen Wipers and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Granting a Joint Motion To Terminate the Investigation Based on a Settlement Agreement U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (‘‘ID’’) (Order No. 29) issued by the presiding administrative law judge (‘‘ALJ’’) granting a joint motion to terminate the investigation based on a settlement agreement. SUMMARY: mstockstill on DSK3G9T082PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Michael Liberman, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–3115. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its Internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation under section 337 of the Tariff Act of 1930, 19 U.S.C. 1337, on August 24, 2015, based on a complaint, as supplemented, filed by Trico Products Corporation of Rochester Hills, Michigan, alleging a violation of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain windscreen wipers and components thereof by reason of infringement of certain claims of U.S. Patent Nos. 6,836,925 and 6,799,348. 80 FR 51309 (Aug. 24, 2015). The respondents are Valeo North America, Inc. of Troy, Michigan, and VerDate Sep<11>2014 19:39 Jul 18, 2016 Jkt 238001 Delmex de Juarez S. de R.L. de C.V. of Parque Industrial Intermex, Cd. Juarez, Chihuahua, Mexico. Id. The Office of Unfair Import Investigations is not participating in the investigation. On May 27, 2016, complainant and respondents filed a joint motion to terminate this investigation in its entirety based on a settlement agreement. On June 20, 2016, the ALJ issued an ID (Order No. 29), granting the motion for termination. The ALJ found that the joint motion complies with the Commission Rules and that termination of the investigation will not adversely affect the public interest. No party petitioned for review of the subject ID. The Commission has determined not to review the ID. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By Order of the Commission. Issued: July 13, 2016. William R. Bishop, Supervisory Hearings and Information Officer. [FR Doc. 2016–17011 Filed 7–18–16; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before September 19, 2016. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments and requests for hearings on applications to import raw material are not appropriate. 72 FR 3417 (January 25, 2007). SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of DATES: PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on May 5, 2016, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616 applied to be registered as a bulk manufacturer the following basic classes of controlled substances: Controlled Substance Schedule Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333) .......................... Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) ................... Opium, powdered (9639) .............. Oxymorphone (9652) .................... Noroxymorphone (9668) ............... Fentanyl (9801) ............................ II II II II II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers, for dosage form development, for clinical trials, and for use in stability qualification studies. Louis J. Milione, Deputy Assistant Administrator. [FR Doc. 2016–17061 Filed 7–18–16; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Rhodes Technologies ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and DATES: E:\FR\FM\19JYN1.SGM 19JYN1

Agencies

[Federal Register Volume 81, Number 138 (Tuesday, July 19, 2016)]
[Notices]
[Page 46956]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-17061]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Cambrex 
Charles City

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.33(a) on or before September 19, 2016.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/ODW, 
8701 Morrissette Drive, Springfield, Virginia 22152. Comments and 
requests for hearings on applications to import raw material are not 
appropriate. 72 FR 3417 (January 25, 2007).

SUPPLEMENTARY INFORMATION: 
    The Attorney General has delegated her authority under the 
Controlled Substances Act to the Administrator of the Drug Enforcement 
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all 
necessary functions with respect to the promulgation and implementation 
of 21 CFR part 1301, incident to the registration of manufacturers, 
distributors, dispensers, importers, and exporters of controlled 
substances (other than final orders in connection with suspension, 
denial, or revocation of registration) has been redelegated to the 
Deputy Assistant Administrator of the DEA Office of Diversion Control 
(``Deputy Assistant Administrator'') pursuant to section 7 of 28 CFR 
part 0, appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on May 5, 
2016, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616 
applied to be registered as a bulk manufacturer the following basic 
classes of controlled substances:

------------------------------------------------------------------------
                     Controlled Substance                       Schedule
------------------------------------------------------------------------
Amphetamine (1100)...........................................         II
Lisdexamfetamine (1205)......................................         II
Methylphenidate (1724).......................................         II
4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333).............         II
Phenylacetone (8501).........................................         II
Cocaine (9041)...............................................         II
Codeine (9050)...............................................         II
Oxycodone (9143).............................................         II
Hydromorphone (9150).........................................         II
Hydrocodone (9193)...........................................         II
Morphine (9300)..............................................         II
Oripavine (9330).............................................         II
Thebaine (9333)..............................................         II
Opium extracts (9610)........................................         II
Opium fluid extract (9620)...................................         II
Opium tincture (9630)........................................         II
Opium, powdered (9639).......................................         II
Oxymorphone (9652)...........................................         II
Noroxymorphone (9668)........................................         II
Fentanyl (9801)..............................................         II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers, for dosage form development, for 
clinical trials, and for use in stability qualification studies.

Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016-17061 Filed 7-18-16; 8:45 am]
 BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.